Precision BioSciences Announces Late-Breaking Poster Presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
09 Novembro 2023 - 9:00AM
Business Wire
Company to Host Webcast and Conference Call
on Monday, November 13, 2023 at 4:30 PM ET
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene
editing company utilizing its novel proprietary ARCUS® platform to
develop in vivo gene editing therapies for sophisticated gene
edits, including gene insertion, excision, and elimination, today
announced that an abstract featuring preclinical data for its
wholly owned PBGENE-HBV program has been accepted for late-breaker
presentation at the American Association for the Study of Liver
Diseases (AASLD) Annual Meeting being held in Boston, MA on
November 10-14, 2023.
Presentation Details:
Title: Preclinical efficacy and safety of ARCUS-POL
nucleases for chronic hepatitis B: a potentially curative strategy
Session Title: Late Breaking Poster Session Poster
Number: 5040-C Presenter: Cassie Gorsuch, VP of Gene
Therapy, Precision Biosciences Date and Time: Monday,
November 13, 2023, 1:00 PM – 2:00 PM EST Location: Hall
C
Company-Hosted Webcast and Conference Call
Information:
Precision will host a conference call and webcast on Monday,
November 13, 2023 at 4:30 PM ET to discuss PBGENE-HBV program
updates. The dial-in conference call number is (800) 715-9871 and
the conference ID number for the call is 3866428. Participants may
access the live webcast, and accompanying presentation materials,
as well as the archived webcast on Precision’s website in the
Investors section under Events & Presentations:
https://investor.precisionbiosciences.com/events-and-presentations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is an advanced gene editing company
dedicated to improving life (DTIL) with its novel and proprietary
ARCUS® genome editing platform that differs from other technologies
in the way it cuts, its smaller size, and its simpler structure.
Key capabilities and differentiating characteristics may enable
ARCUS nucleases to drive more intended, defined therapeutic
outcomes. Using ARCUS, the Company’s pipeline is comprised of in
vivo gene editing candidates designed to deliver lasting cures for
the broadest range of genetic and infectious diseases where no
adequate treatments exist. For more information about Precision
BioSciences, please visit www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231109531717/en/
Investor and Media Contact: Mei Burris Senior Director of
Finance and Corporate Controller
Mei.Burris@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Precision BioSciences (NASDAQ:DTIL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024